Cargando…
RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancer
Current targeted cancer therapies are largely guided by mutations of a single gene, which overlooks concurrent genomic alterations. Here, we show that RNASEH2B, RB1, and BRCA2, three closely located genes on chromosome 13q, are frequently deleted in prostate cancer individually or jointly. Loss of R...
Autores principales: | Miao, Chenkui, Tsujino, Takuya, Takai, Tomoaki, Gui, Fu, Tsutsumi, Takeshi, Sztupinszki, Zsofia, Wang, Zengjun, Azuma, Haruhito, Szallasi, Zoltan, Mouw, Kent W., Zou, Lee, Kibel, Adam S., Jia, Li |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for the Advancement of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8856618/ https://www.ncbi.nlm.nih.gov/pubmed/35179959 http://dx.doi.org/10.1126/sciadv.abl9794 |
Ejemplares similares
-
CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer
por: Tsujino, Takuya, et al.
Publicado: (2023) -
RB1 loss triggers dependence on ESRRG in retinoblastoma
por: Field, Matthew G., et al.
Publicado: (2022) -
PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer
por: Dillon, Kasia M., et al.
Publicado: (2022) -
ATM deficiency confers specific therapeutic vulnerabilities in bladder cancer
por: Zhou, Yuzhen, et al.
Publicado: (2023) -
Clinical PARP inhibitors allosterically induce PARP2 retention on DNA
por: Langelier, Marie-France, et al.
Publicado: (2023)